PLASMID DNA TO INDUCE IMMUNITY TO INTRACELLULAR PATHOGEN

控制传染病的免疫方法，其中裸质粒DNA作为“免疫原”注射，已经在有限数量的病毒模型中进行了测试，这些初步研究的结果引起了很大的兴奋。 质粒DNA免疫有望提供一种刺激体液和细胞免疫应答的独特方法，它代表了传统疫苗开发方法的一种有吸引力的替代方法。 事实上，诱导特异性细胞介导的免疫应答的能力是许多临床使用可接受的疫苗制剂未实现的目标。 这是疫苗开发中的关键考虑因素，因为消除大多数细胞内病原体需要细胞介导的免疫应答。 在我们的I期研究中，我们成功地证明了对细胞内病原体单核细胞增生李斯特菌的免疫可以通过使用编码用于免疫的毒力因子的质粒DNA的基因免疫来诱导。 这种免疫导致细胞毒性细胞的发展，如在体外测量的，并针对用活的L.单核细胞增多症 在我们提出的II期研究中，我们将扩大这些研究，以优化和验证这种有前途的方法的使用，以开发保护性细胞介导的免疫性兼性细胞内病原体。拟议的商业应用：控制许多传染病原的疫苗仍有待开发。 最值得注意的是缺乏疫苗，可以导致保护性细胞介导的免疫细胞内病原体的发展。 需要开发用于遗传免疫的改进试剂，因为这一技术适用于针对兼性细胞内寄生虫的有效免疫。

The method of immunization for the control of infectious diseases in which naked plasmid DNA is injected as the "immunogen" has been tested in a limited number of viral models and the results of these initial studies have caused much excitement. Plasmid DNA immunization promises to offer a unique method of stimulating both humor and cellular immune responses and it represents an attractive alternative to conventional approaches of vaccine development. Indeed, the ability to indue a specific cell-mediated immune response is a system an unfulfilled goal of many vaccine formulations acceptable for clinical use. This is critical consideration in vaccine development, as a cell-mediated immune response is required for the elimination of most intracellular pathogens. In our Phase I study w4e successful demonstrated that immunity to the intracellular pathogen Listeria monocytogenes can be induced by genetic immunization using plasmid DNA encoding a virulence factor for immunization. This immunization lead to the development of cytotoxic cells as measured in vitro and to protective immunity against challenge with viable L. monocytogenes. In our proposed Phase II studies we will expand these studies in order to optimize and validate the use of this promising approach to develop protective cell-mediated immunity to facultative intracellular pathogens. PROPOSED COMMERCIAL APPLICATION: Vaccines for the control of many infectious agents remain to be developed. Most notable is the absence of vaccines that can cause the development of protective cell-mediated immunity to intracellular pathogens. Development of improved reagents for genetic immunization is required as is the demonstration that this technology is suitable for effective immunization against facultative intracellular parasites.